Annexon Biosciences, Inc. (ANNX) has disclosed a new risk, in the Capital Markets category.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Annexon Biosciences, Inc. faces significant risks due to its reliance on international third-party suppliers in a volatile global trade environment. The company’s dependence on foreign manufacturing for its product candidates, tanruprubart and vonaprument, exposes it to potential disruptions from tariffs, sanctions, and trade barriers. These factors could lead to increased research and development costs, supply chain complexities, and delays in development timelines, ultimately affecting its financial condition and growth prospects. The uncertainty surrounding international trade policies necessitates vigilant risk management to mitigate potential adverse impacts on its operations.
The average ANNX stock price target is $11.00, implying 350.82% upside potential.
To learn more about Annexon Biosciences, Inc.’s risk factors, click here.